Chandler Robinson, Chief Executive Officer at Monopar Therapeutics, sold MNPR on Sep 24, 2026
Data as of Oct 16
▼ SELL$911K10,450 shares at $87.15Chandler Robinson Chief Executive OfficerMNPR Monopar Therapeutics
- Traded
- Sep 24, 2026
- Disclosed
- Sep 28, 2026
- Filed
- 4 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
MNPR since disclosure
−17.3%
after the sale
Similar stocks (XLV) since disclosure
+3.2%
XLV — its sector index fund
Change in closing price from Sep 28, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLChandler Robinson Chief Executive OfficerMNPR Monopar Therapeutics$848Kdisclosed Sep 28 · filed 4 days after the trade
- ▼ SELLChandler Robinson Chief Executive OfficerMNPR Monopar Therapeutics$53.9Kdisclosed Sep 28 · filed 4 days after the trade
- ▼ SELLChandler Robinson Chief Executive OfficerMNPR Monopar Therapeutics$745Kdisclosed Sep 28 · filed 4 days after the trade